Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More
Neurology
2022 – the year in review
November 29, 2022Take the survey: Looking back on 2022
In 2022, the most noteworthy event was the announcement that the COVID-19 pandemic was over. That was reassuring news, although there have been 316 million reported cases this year, about 50% of all COVID cases to date. Canada saw an average of 48 COVID-related deaths per day post-pandemic. Read More
SPMS pathogenesis and treatment
November 14, 2022ECTRIMS Special Report
Secondary-progressive multiple sclerosis (SPMS) was an area of special interest at the recent European Committee for Treatment and Research in MS (ECTRIMS) annual meeting, held October 26-28 in Amsterdam, The Netherlands. Read More
ECTRIMS 2022 SLIDE DECK
November 10, 2022Selected highlights from the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Amsterdam, The Netherlands
26-28 October 2022
62 slides with notes
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada Read More
ECTRIMS 2022 HIGHLIGHTS – SATURDAY, OCTOBER 29 EDITION
October 29, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 3 of ECTRIMS 2022.